ArticleBiomaterials2010
PET/NIRF/MRI triple functional iron oxide nanoparticles.
Article in Biomaterials, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 487 citations in OpenAlex.
- Innovative Designs of Multimodal Imaging Based on Radionuclide, Quantum, and Cargo-Loaded Nanoplatform Emitters Towards Enhanced Energy-Matter Interactions for Photonics and Bioassays.Materials (Basel, Switzerland) · 2026Review
- Albumin Nanoparticles as Multifunctional Carriers for Advanced Therapeutics.Pharmaceutics · 2026Review
- Radiolabeled Iron-Based Nanomaterials for Cancer Diagnosis and Therapy.International journal of nanomedicine · 2026Review
- Therapeutic Approaches with Iron Oxide Nanoparticles to Induce Ferroptosis and Overcome Radioresistance in Cancers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A Modular Approach to Obtain HER2-Targeting DM1-Loaded Nanoparticles for Gastric Cancer Therapy.ACS omega · 2024Article
- Review
- Exploring innovative strides in radiolabeled nanoparticle progress for multimodality cancer imaging and theranostic applications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Article
- Advances and prospects of precision nanomedicine in personalized tumor theranostics.Frontiers in cell and developmental biology · 2024Review
- Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review.International journal of molecular sciences · 2023Review
- Functional Diversity in Radiolabeled Nanoceramics and Related Biomaterials for the Multimodal Imaging of Tumors.ACS bio & med chem Au · 2023Review
- Review
- Iron Nanoparticles Open Up New Directions for Promoting Healing in Chronic Wounds in the Context of Bacterial Infection.Pharmaceutics · 2023Review
- Inorganic nanoparticles as scaffolds for bioorthogonal catalysts.Advanced drug delivery reviews · 2023Review
- Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT/MRI and PET/MRI.Nanomaterials (Basel, Switzerland) · 2023Review
- Nanomaterial-based contrast agents.Nature reviews. Methods primers · 2023Article
- Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update.Journal of nanobiotechnology · 2022Review
- Effects of folate-conjugated FeMedical oncology (Northwood, London, England) · 2022Article
- Nanomaterial Probes for Nuclear Imaging.Nanomaterials (Basel, Switzerland) · 2022Review
- Protein nanoparticles directed cancer imaging and therapy.Nano convergence · 2022Review
85 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Engineered nanoparticles with theranostic functions have attracted a lot of attention for their potential role in the dawning era of personalized medicine. Iron oxide nanoparticles (IONPs), with their advantages of being non-toxic, biodegradable and inexpensive, are candidate platforms for the buildup of theranostic nanostructures; however, progress in using them has been limited largely due to inefficient drug loading and delivery. In the current study, we utilized dopamine to modify the surface of IONPs, yielding nanoconjugates that can be easily encapsulated into human serum albumin (HSA) matrices (clinically utilized drug carriers). This nanosystem is well-suited for dual encapsulation of IONPs and drug molecules, because the encapsulation is achieved in a way that is similar to common drug loading. To assess the biophysical characteristics of this novel nanosystem, the HSA coated IONPs (HSA-IONPs) were dually labeled with (64)Cu-DOTA and Cy5.5, and tested in a subcutaneous U87MG xenograft mouse model. In vivo positron emission tomography (PET)/near-infrared fluorescence (NIRF)/magnetic resonance imaging (MRI) tri-modality imaging, and ex vivo analyses and histological examinations were carefully conducted to investigate the in vivo behavior of the nanostructures. With the compact HSA coating, the HSA-IONPs manifested a prolonged circulation half-life; more impressively, they showed massive accumulation in lesions, high extravasation rate, and low uptake of the particles by macrophages at the tumor area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.